Recent research have converged on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopaminergic signaling. While GLP activators are commonly employed for treating type 2 diabetes, their potential impacts on motivation circuits, specifically mediated by dopamine systems, are attracting substantial … Read More